Ion channels in EEG: isolating channel dysfunction in NMDA receptor antibody encephalitis by Symmonds, M et al.
Ion channels in EEG: isolating channel
dysfunction in NMDA receptor antibody
encephalitis
Mkael Symmonds,1,2,3 Catherine H. Moran,4 M. Isabel Leite,1,5 Camilla Buckley,1
Sarosh R. Irani,1,5 Klaas Enno Stephan,6 Karl J. Friston7 and Rosalyn J. Moran8,9
See Roberts and Breakspear (doi:10.1093/brain/awy136) for a scientiﬁc commentary on this article.
Neurological and psychiatric practice frequently lack diagnostic probes that can assess mechanisms of neuronal communication
non-invasively in humans. In N-methyl-D-aspartate (NMDA) receptor antibody encephalitis, functional molecular assays are par-
ticularly important given the presence of NMDA antibodies in healthy populations, the multifarious symptomology and the lack of
radiological signs. Recent advances in biophysical modelling techniques suggest that inferring cellular-level properties of neural
circuits from macroscopic measures of brain activity is possible. Here, we estimated receptor function from EEG in patients with
NMDA receptor antibody encephalitis (n = 29) as well as from encephalopathic and neurological patient controls (n = 36). We
show that the autoimmune patients exhibit distinct fronto-parietal network changes from which ion channel estimates can be
obtained using a microcircuit model. Speciﬁcally, a dynamic causal model of EEG data applied to spontaneous brain responses
identiﬁes a selective deﬁcit in signalling at NMDA receptors in patients with NMDA receptor antibody encephalitis but not at other
ionotropic receptors. Moreover, though these changes are observed across brain regions, these effects predominate at the NMDA
receptors of excitatory neurons rather than at inhibitory interneurons. Given that EEG is a ubiquitously available clinical method,
our ﬁndings suggest a unique re-purposing of EEG data as an assay of brain network dysfunction at the molecular level.
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Introduction
N-Methyl-D-aspartate receptor (NMDAR) antibody enceph-
alitis, ﬁrst described in 2007, is an autoimmune disorder
with diverse psychiatric and neurological features, most
commonly psychosis, disorientation, amnesia, seizures and
a complex movement disorder (Dalmau et al., 2011). EEG
is frequently performed in initial clinical investigations to
assess the degree of encephalopathy and to detect the pres-
ence of seizures (Irani et al., 2010b). EEG ﬁndings can vary
from normal to encephalopathic without any speciﬁc diag-
nostic indicators although a ‘delta-brush’ (Schmitt et al.,
2012) pattern has been described in some patients. MRI
ﬁndings too, are likely to be normal in the majority of pa-
tients (Irani et al., 2010b). The diagnosis of NMDAR-anti-
body encephalitis is based on a typical clinical phenotype,
with the demonstration of autoantibodies in CSF and serum.
However, clinical presentations can be highly heterogeneous,
making diagnosis challenging (Graus et al., 2010; Je´ze´quel
et al., 2017). Improved short- and long-term clinical
outcomes are dependent upon early institution of immu-
notherapies, which aim to reduce autoantibody levels and
the accompanying immune-system activation (Gabilondo
et al., 2011). A non-invasive measure of NMDAR func-
tion could thus facilitate early diagnosis and treatment,
and provide the ability to track therapeutic response
with a speciﬁc biomarker of disease activity. Overall, the
ability to non-invasively assay synaptic ion channel function
in clinical settings would translate our growing molecular
understandings of psychiatric and neurological diseases
into novel tools for clinical practice (Lisman, 2012; Friston
et al., 2016a). If successful, such assays would allow for
detecting ion channel disruptions across a wide class
of illnesses, not limited to those with an immunological
aetiology.
NMDAR-antibody encephalitis provides an ideal testbed
for developing a speciﬁc non-invasive measure of ion chan-
nel dysfunction in vivo in humans. Here we present
evidence for identifying aberrant channel signalling using
dynamic causal models (DCMs) for EEG-derived cross-
spectral recordings (Moran et al., 2008). DCMs use neuro-
biologically-interpretable mathematical models of neuronal
ensembles to predict ﬂuctuations in synaptic currents and
their inﬂuence on postsynaptic membrane potentials as
measured with EEG. The model comprises three levels of
description. At the lowest level, dynamic equations describe
the ﬂow of particular ions at the synapse. Then, at the
population level, interactions of groups of synapses
describe a connected local circuit. Finally the summed
local circuit currents are adjusted using appropriate for-
ward models to mimic transmission from the neuronal
source through the scalp to the recording electrode
(Kiebel et al., 2006). Crucially, DCM allows for solving
the ‘inverse problem’ of inferring, from individual patient
recordings, the most likely biophysical parameters that gen-
erated the measured brain activity.
Here we tested whether this approach can reveal the spe-
ciﬁc ion channel abnormality in 29 patients with NMDAR-
antibody encephalitis. We aimed to determine whether
NMDA parameter estimates are selectively identiﬁed as
abnormal, using standard clinical EEG and a DCM that
incorporates signalling at NMDA, AMPA and GABAA re-
ceptors. We also aimed to test whether particular cell types
were more or less affected. In what follows we ﬁrst show
that cross-spectra generated from spontaneous (‘resting
state’) EEG measurements from patients with NMDAR-
antibody encephalitis exhibited differences when compared
to encephalopathic patient controls (a range of causes of
encephalopathy without NMDAR antibodies, n = 18) and
neurological patient controls (n = 18) who underwent a
clinical EEG. We then show that these spectral differences
could be captured by DCM, with subject-speciﬁc model
parameters reﬂecting the underlying mapping from ion
channels to EEG spectra. Using an empirical Bayesian ap-
proach (Friston et al., 2016b) we revealed that the effect of
NMDAR-antibody encephalitis is expressed selectively in
the DCMs’ inferred NMDAR parameters, in line with the
underlying synaptic abnormality.
Materials and methods
Patient diagnosis and clinical status
Retrospective data collection had research approval from
Oxford University Hospitals NHS Trust. Anonymized
retrospective EEG were collected from patients with a clinical
diagnosis of NMDAR-antibody encephalitis based on one or
more typical clinical features (abnormal psychiatric behaviour
or cognitive dysfunction, speech dysfunction (pressured
speech, dysphasia/mutism), seizures, movement disorders
(dyskinesia, rigidity, dystonias), decreased consciousness, auto-
nomic dysfunction) and positive serology for NMDAR antibo-
dies during their illness (either serum and or CSF antibodies to
the GluN1 subunit of the NMDAR) (Graus et al., 2016). They
underwent routine EEG at the tertiary centre either early in the
course of their illness or following assessment for relapse or
persistent symptoms and positive serology despite immunosup-
pressive treatment. In addition, data were collected from
patients with encephalopathy from a range of metabolic, in-
ﬂammatory and structural causes, as well as a separate cohort
of non-encephalopathic patients with neurological symptoms
requiring an EEG as part of standard clinical management.
Clinical details of included patients are summarized in
Supplementary Tables 1–3.
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EEG acquisition and preprocessing
Routine clinical EEG data had been collected from adults (inpa-
tients and outpatients) at rest for 30–60min. Acquisition used a
standard 10-20 montage set-up with 21 channel recording and
clinical-grade ampliﬁers (Natus). Impedances of all electrodes
were 55 k prior to data acquisition. During acquisition,
data were sampled at 250–500Hz. Data were exported and
epoched into 5-s segments and visually inspected to remove
epochs containing large baseline shifts, eye blink or movement
artefacts, or overt discharges using the Fieldtrip toolbox in
MATLAB (Mathworks, Natick, USA). This resulted in an aver-
age of 12min of wake resting state data post artefact correction
(144 trials of 5-s epochs). These data were low-pass ﬁltered at
42Hz. For data processing we used the analysis routines avail-
able in the academic open source software SPM12 (Wellcome
Trust Centre for Neuroimaging, London, UK, http://www.ﬁl.ion.
ucl.ac.uk/spm/). These 21-channel sensor data were decomposed
into eight spatial principal modes to reduce complexity in model
ﬁtting using singular value decomposition.
Spectral analysis
To summarize the epoched resting state data and obtain data
features for model ﬁtting, we used a sensor-space representation.
We speciﬁcally retained eight singular vectors that summarized
the spatial distribution of responses on the scalp. Using these
time series we then applied an autoregressive method developed
to calculate the complex cross spectral energy across these eight
spatial modes, including the real auto-spectral energies and com-
plex cross-spectral energies. This produced a symmetric 8  8
matrix of cross-spectral energy in sensor space. Thus, we had a
matrix of 1856 real and 1856 complex data points to ﬁt for
each subject for the beta-gamma band DCM (20–48Hz) and
320 real and 320 complex data points to ﬁt for each subject for
the delta-theta (2–6Hz) band DCM. To produce the model-
based recapitulation of these data we ﬁrst generated data in
source space with the model using the dynamics described in
Supplementary Fig. 7. We then passed this 4-source data
through the leadﬁeld, calculated from a ﬁnite element model
(SPM’s standard EEG leadﬁeld procedure) and reproduced the
spatial modes with an identical mixture of channels as the ori-
ginal data-driven solution. Thus, we ﬁt the model based on
these sensor-level data and sensor-based modelled replications.
We illustrate this procedure in full in Supplementary Fig. 1.
We summarized model ﬁt as per cent variance explained
(i.e. R2). This was calculated as the squared correlation coef-
ﬁcient between the data-derived and the model-predicted
complex cross-spectral responses (we concatenate the matrix
of cross spectral responses into a vector of absolute values to
perform the calculation).
To test for summary differences over groups in the beta-
gamma spectra we used an analysis of variance over the aver-
age absolute power from 28 to 40Hz. This power measure
was taken from the ﬁrst principal mode’s autospectral re-
sponse. For the shorter delta-theta band we performed a sum-
mary analysis on the average response from 2 to 4Hz, here
taking the second principal mode. To investigate the direction
of group effects post hoc, we applied t-tests and corrected for
multiple comparisons.
Dynamic causal modelling
In DCM the neural mass models have been developed based
on known cortical anatomy and physiology. We implemented
a conductance-based model, with brain regions modelled as
interconnected neural masses with speciﬁc inter- and intra-
regional connectivity. These same models have been previously
extensively applied to electrophysiological data in animals and
humans (a full discussion and overview of the development
and implementation of these models can be found in
Marreiros et al., 2009; Moran et al., 2013).
We used the canonical microcircuit model (CMC) for DCM
(Bastos et al., 2012), with NMDARs (spm_fx_cmm_nmda),
which accounts for laminar differences in the origin of forward
and backward connections in the brain (superﬁcial versus deep
pyramidal cells, respectively). We applied anatomical priors cor-
responding to a default mode (resting state) network with four
source locations based on previous MEG reports (Baker et al.,
2014), with left and right parietal cortical sources at MNI lo-
cations [29 68 49] and [29 68 49], respectively, and left
and right prefrontal sources at MNI locations [33 45 28]
and [33 45 28], respectively (Fig. 2A). The CMC that we
used comprised excitatory and inhibitory extrinsic connection
parameters from four distinct cell layers: superﬁcial pyramidal
cells, spiny stellate cells, deep pyramidal cells, and inhibitory
interneurons (Fig. 2B). Within the model, superﬁcial pyramidal
cells in the parietal sources carry signals to spiny stellate cells
and deep pyramidal cells in a feedforward manner up the cor-
tical hierarchy, while deep pyramidal cells carry top-down
signals in a feedback manner from frontal cortex to both super-
ﬁcial pyramidal cells and inhibitory interneurons in the parietal
sources.
In terms of the physiological mechanisms of connectivity, the
dynamics of postsynaptic responses are modelled as capacitive
synaptic current ﬂow across the synaptic membrane; a summary
of generic equations dictating the dynamics of one cellular
population are shown in Supplementary Fig. 7, and detailed
equations can be found in Moran et al. (2011b). The active
currents across the postsynaptic membrane include ligand-
gated inhibitory (Cl) and excitatory (Na+ /Ca2+ ) and ion
ﬂow mediated by fast GABAA and AMPA receptors and
slower NMDARs, respectively. Each neuronal subpopulation
has one voltage/membrane-depolarization state and three con-
ductances (AMPA, GABAA and NMDA). Thus, each subpopu-
lation has four states. With four populations per source and
four sources, which amounts to 64 coupled ordinary differential
equations (ODEs) for a given inversion. Hence there are 64
potential ‘poles’—regions of inﬁnite frequency response that
are solutions to the characteristic equation of the dynamic
system—which are all mixtures of the model parameters. The
magnesium block at NMDARs is voltage-gated and non-linear.
In our model the NMDAR conductance is thus augmented by a
parameterized non-linear sigmoid gain function (Supplementary
Fig. 7, with three parameters as proposed by Durstewitz et al.,
2000). Reversal potentials for sodium, calcium and chloride
were ﬁxed at 60mV, 10mV and 70mV, respectively. A po-
tassium leak current was used to account for all passive ionic
currents, with V_L (reversal potential) 70mV. The model also
included a driving current input, which enters the spiny stellate
cells. The conductances of these ligand-gated ion channels are
dynamic states in our model described by differential equations
(Supplementary Fig. 7). The conductance reﬂects the number of
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open channels, which depends upon the coupling of presynaptic
input to the postsynaptic response, and the channel’s time con-
stant with prior values of 12ms, 8ms and 100ms, for AMPA,
GABAA and NMDARs, respectively. Importantly, the inverse of
the time constants are known as rate constants and are critical
parameters of our model as they represent the rate of channel
opening. The presynaptic ﬁring is controlled by the membrane
potential of the efferent cell population. The speciﬁc code for
this implementation can be found in the academic freeware in
http://www.ﬁl.ion.ucl.ac.uk/spm/toolbox/DCMMEEG.
For the DCM analyses, EEG activity were ﬁtted over two
frequency bands (20–48 Hz and 2–6Hz) using two identical
DCMs. DCM optimizes a posterior density over free param-
eters (parameterized by its mean and covariance) via a vari-
ational Bayesian inversion procedure giving a trade off in
accuracy and complexity (Friston et al., 2007). To set prior
parameter values we inverted DCMs for three neurological
patient controls selected at random and used their average
posterior parameter values as prior values for DCM inversions
of all other subjects in all groups. This was to ensure we had
found a (local) maximum, i.e. an optimum parameter setting
for the groups generally and prevented any bias in model
parameters between the groups. We harvested the parameter
estimates from optimized DCMs for the two models and used
a canonical variates analysis (spm_CVA) to assess group
differences amongst parameter sets. These sets comprised
parameters speciﬁc to NMDA, AMPA and GABAA receptors
(Supplementary Fig. 3 and Supplementary Table 4). Canonical
variates analysis is a general method subsuming (multivariate)
linear regression, canonical correlation analysis, multivariate
analysis of variance, discriminant analysis, and Hotelling’s
T-test (Hair et al., 1998). Subject-speciﬁc estimates of the
model parameters across groups are submitted to a linear ana-
lysis testing speciﬁcally for group differences. The results of
this produce a principal canonical vector (weights over param-
eters) and canonical variate (weights over subjects). The ca-
nonical vector speciﬁes the weights of the parameter mixture
that yields the greatest correlation with the mixture of
explanatory variables (here, group differences). That is, the
canonical vector provides the optimal contrast over parameters
to yield the maximal group differences.
For the Bayesian analysis, we applied a recent second level
modelling extension to DCM that allows for random effects
across groups. This so called parametric empirical Bayesian
scheme reﬁts a ‘full model’ (where all parameters can co-
vary according to group designation) and produces reduced
models where all smaller combinations of parameter variation
are considered and informed by the group averages. Here
we apply two group designations, presence or absence of
NMDAR-antibody encephalitis diagnostic label and presence
or absence of encephalopathy. These two groupings were
included in our second-level design matrix, which had three
columns. The ﬁrst column represented the average effect (and
contained ones), the second column described the encephalitis
effects (and comprised ones for NMDAR-antibody encephalitis
patients, ones for other encephalopathy patients and zeros for
non-encephalopathic patients), the third column described the
effect of NMDAR-antibody encephalitis (and comprised ones
for NMDAR-antibody encephalitis patients, zeros for other
encephalopathy patients and zeros for non-encephalopathic
patients). We were most interested in how the third column
of the design matrix was represented by differences in the
DCM parameters within our cohort. We hypothesized that
the second effect (encephalopathy) should be represented by
changes in multiple ion channels. We hypothesized that the
third effect (of NMDAR-antibody encephalitis) should be rep-
resented by changes in NMDA parameters only. We report
those parameters that exhibit signiﬁcant effects of NMDAR-
antibody encephalitis and those parameters that exhibit signiﬁ-
cant effects of encephalopathy using a probability of P4 0.95.
Of note, here we examine parameter-speciﬁc rather than
model-speciﬁc effects. The underlying free energy of the para-
metric empiric Bayes model pertains to all the subject data
from all the groups, assuming random parametric effects at
the between-subject level as well as group-speciﬁc effects in
the hierarchical model (Friston et al., 2016b).
Results
Resting state power spectra exhibit
group differences
The data in the current study comprised resting state,
eyes open, recordings acquired in one sitting, from 29 pa-
tients with NMDAR-antibody encephalitis (Supplementary
Table 1), 18 encephalopathic controls (with encephalop-
athy non-related to a speciﬁc autoimmune channelopathy,
Supplementary Table 2) and 18 neurological patient con-
trol participants (Supplementary Table 3). We investigated
the cross-spectrum of these recordings, which summarizes
longer, spontaneous recordings (Fig. 1A) into a set of
second-order auto and cross-correlation statistics
(Fig. 1B), where ﬁts are performed on sensor-space, com-
plex, cross spectral energies (Supplementary Fig. 1). We
aimed to determine whether particular frequencies could
be discriminated across the groups for subsequent DCM
analysis, including high frequency beta-gamma band re-
sponses (20–48Hz) and lower frequency delta-theta band
responses (2–6Hz), as in previous EEG ﬁndings on
NMDAR-antibody encephalitis (Dalmau et al., 2011;
Schmitt et al., 2012).
The patients with NMDAR-antibody encephalitis had be-
havioural changes ranging from subtle encephalopathic fea-
tures to gross obtundation or unresponsiveness, which were
graded using the West Haven encephalopathy scale
(Supplementary Table 5). Overall, there was no difference
in clinical severity of encephalopathy between the
NMDAR-antibody encephalitis compared to the encephal-
opathy group (Fig. 1A). However, there were differences in
the cross spectrum at particular frequencies. In the delta-
theta band, an analysis of variance revealed signiﬁcant dif-
ferences in power at low (2–4Hz) frequencies (F = 6.0,
P = 0.004; Fig. 1B), with a post hoc analysis showing sig-
niﬁcant increases for the ‘other’ encephalopathy group
compared to the neurological patient controls (P = 0.003
corrected) and compared to the NMDAR-antibody enceph-
alitis group (P = 0.043 corrected). At higher frequencies
(28–40 Hz) we also observed signiﬁcant differences be-
tween the three groups (F = 3.63; P = 0.03) with increased
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beta-gamma power present in the spontaneous spectrum of
patients with NMDAR-antibody encephalitis relative to
neurological patient controls (P = 0.03 corrected, Fig. 1B).
These sensor-level group differences in EEG activity es-
tablished an explanandum to which we could apply our
DCM with ion channel parameters. Using data from the
delta-theta band and data from the beta-gamma band, we
sought to ﬁt two DCMs (Fig. 2) to each set of subject-
speciﬁc spectral responses, creating a multivariate mapping
from model parameters representing dynamics at NMDA,
AMPA and GABAA receptors to these spectral data
features.
Model fits capture spectral responses
Given our resting state paradigm, we used a priori source
locations based on a previous comprehensive study of resting
state magnetoencephalographic networks (Baker et al., 2014),
which showed prominent bilateral parietal and medial frontal
gyrus activity at rest—commensurate with the default mode
network observed in functional MRI studies (but without a
precuneus source) (Brookes et al., 2011). Thus four connected
sources, with four interhemispheric connections, were used to
describe delta-theta and beta-gamma cross-spectrum observed
at the scalp sensors (Fig. 2A): with parietal sources sending
forward connections to frontal sources and frontal sources
sending backward connections to parietal sources within
each hemisphere (Moran et al., 2008). Each source comprised
a neural mass model that had four neuronal subpopulations
(superﬁcial and deep pyramidal cells, inhibitory interneurons
and layer IV stellate cells) with dynamics determined by in-
trinsic connections mediated via NMDA, AMPA and GABAA
receptors (Fig. 2B). These models have been extensively de-
veloped and used for modelling electrophysiological data in
humans and animals (for a review see Moran et al., 2013).
Of particular note, NMDARs have relatively slow time
Figure 1 Spectral characteristics of NMDAR-antibody encephalitis. (A) Left: EEG, scalp data from mid-frontal channel Fz from ex-
emplar patients in each group. Right: Though NMDAR-antibody encephalitis can present with a range of clinical and electrographic features there
was no statistical difference in the clinical severity of encephalopathy (West-Haven scale) applied to the two groups. Inset shows merged
fluorescence image of cell-based assay of positive NMDAR antibodies in serum. (B) On the far left, scalp maps indicate the 21 sensor locations and
power estimates from two exemplar subjects. In the left panel we show the spontaneous delta-theta and high beta-gamma power averaged across
the groups. Given previous reports of altered low (delta/theta) and high (beta/agama) frequency power in patients with NMDAR-antibody
encephalitis, we tested these ranges and found a significant effect of group [right panel (log-log plot of spectral power)]. For delta responses the
spectral differences were driven by enhanced power from 2 to 4 Hz in the control encephalopathic patients (ANOVA: F = 6.0, P = 0.004). For the
beta/gamma band it was the NMDAR-antibody encephalitis group that exhibited the greatest power (ANOVA: F = 3.63; P = 0.03). The average
response over the band is plotted for each subject (x’s) with inverted triangles indicating the group mean.
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constants compared to AMPA receptors (12ms versus
100ms), which leads to distinct dynamical properties.
Model inversion proceeds by optimizing the model free
energy, a bound on the model evidence, using a variational
Bayesian estimation scheme, which accounts for dependencies
amongst parameters (Supplementary material). Together, dy-
namics along these intrinsic (between subpopulations within a
source) and extrinsic (between sources) connections could re-
produce the scalp-based EEG recordings (Fig. 2C). We found
that our beta-gamma models provided excellent ﬁts to the
data with an average per cent variance explained of 86%,
88% and 94% for our NMDAR-antibody encephalitis, other
encephalopathy and neurological patient controls, respect-
ively, and no signiﬁcant differences in ﬁt across the groups
(Fig. 2C). For the delta-theta models the variance explained
was lower with 77%, 74% and 71% variance explained for
the three groups.
We also performed a comparison with a model including
an interconnection from the superﬁcial pyramidal cells to
the layer IV spiny stellate cells, given that stellate cells also
express NMDARs (Moran et al., 2013). We ﬁtted this new
model, with the additional connections to all of our data-
set, and then performed a statistical model comparison
(Supplementary Fig. 2). Interestingly, this revealed that
our original model was favoured when ﬁtting spectral re-
sponses in the beta and gamma range (consistent with the
literature hypothesizing a pyramidal-interneuron gamma
mechanism for high frequency oscillations) (Wulff et al.,
2009; Gonzalez-Burgos and Lewis, 2012), while the aug-
mented models with NMDAR input to layer IV cells was
favoured when ﬁtting the delta-band spectrum. This dem-
onstrates that the estimates are robust to changes in model
structure, but provides additional insight that accounting
for NMDARs on stellate cells improves the ability of the
model to explain slow frequency responses in our patients.
Importantly, however, this effect does not improve discrim-
ination between NMDAR antibody encephalitis and ence-
phalopathic control patients in our sample. Crucially there
Figure 2 The DCM. (A) Sources for the DCM are based on MEG ‘default mode’ studies and comprise two parietal and two frontal sources.
These are connected with forward connections (from supragranular layers) from parietal to frontal cortex and with backward connections (from
infragranular layers) from frontal to parietal cortex. (B) Each source is populated with a four-population neural mass model comprising supragranular
pyramidal cells, inhibitory interneurons, layer IV stellate cells and infragranular pyramidal cell layer. Receptors and intrinsic connections represented in
the neural mass models are shown. Our dynamics prescribe changes in postsynaptic membrane potential based on the dynamics of ion channel
transmission (Supplementary Fig. 4). These ions are controlled by conductances representing binding to GABAA, NMDA and AMPA receptors. Each
of these receptors is imbued with a physiologically plausible time constant, which acts as the inverse of a rate constant controlling the rate of opening
and closing. Each channel also has its own reversal potential set at physiological levels (see text). (C) The DCMs produce spectra, which recapitulate
the patterns of beta-gamma and delta-theta responses observed in the empirical recordings. Importantly, no group effects of fit were observed. In
other words, the model was equally applicable to all data. C = patient controls; E = other encephalopathy; N = NMDA encephalitis.
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were no signiﬁcant group differences in data ﬁts in the
delta-theta models (Fig. 2C) either. Thus, we show that
the models comprising four sources (each with four neur-
onal subpopulations) recapitulated the original EEG data.
Ion channel measures: specific group
differences in NMDA parameters
We assessed whether the optimized model parameters re-
ﬂected the true underlying synaptic deﬁcit. In particular, we
sought to determine whether decreased receptor signalling
at NMDARs in patients with NMDAR-antibody encephal-
itis would be represented by a speciﬁc abnormality in par-
ameters that control NMDAR conductances in the model.
Each DCM comprised 41 neuronal parameters. These
included: a rate constant for each of the three receptors
(NMDA, AMPA and GABAA) in each of the four sources
(3  4 parameters); an intrinsic connection strength
describing the weight of presynaptic ﬁring on each of the
three postsynaptic receptors (3  4 parameters), with sep-
arate weights for NMDAR-mediated inputs to inhibitory
and excitatory neurons (four parameters); an extrinsic
connection strength describing the weight of forward con-
nections, i.e. presynaptic parietal ﬁring on postsynaptic
frontal responses at AMPA receptors for both hemispheres
(two parameters), and similarly for backward connections
(two parameters); a parameter describing the variance in
ensemble ﬁring (one parameter); a parameter describing
background current (one parameter); three parameters
controlling the magnesium block, voltage-dependent non-
linearity of the NMDA channels (three parameters); and
ﬁnally, a time delay for synaptic transmission within each
of the four sources (four parameters). Alterations in these
model parameters have non-linear interactive effects on
model dynamics. In Supplementary Fig. 7 we simulate the
individual and dual effects of non-linearity and slower time
constants of the modelled NMDAR. Interestingly both dy-
namic components of the channel alter the spectra output
of the neural mass revealing a non-isomorphic relationship
between spectral frequency content and time constants of
the receptor.
Thus, for each model, we could order our parameters
into three ion-channel sets, a set of NMDAR parameters
(15 parameters in total), a set of AMPA receptor param-
eters (12 parameters in total) and a set of GABAA receptor
parameters (eight parameters in total, Supplementary Table
4). To determine whether particular ion channel parameters
exhibited signiﬁcant group differences, we ﬁrst used a ca-
nonical variates analysis (CVA) on the a posteriori expect-
ations (model estimates) of the parameters (Fig. 3 and
Supplementary Fig. 4). Speciﬁcally, we were interested in
a signiﬁcant mapping from the multivariate parameter esti-
mates from each ion channel set to the diagnosis of
NMDAR-antibody encephalitis. Three CVAs for each set
of NMDA, AMPA and GABAA were thus conducted to
test for signiﬁcant differences between patients with or
without NMDAR-antibody encephalitis. The parameter
sets for each ion channel comprised optimized individual
estimates from both the delta-theta and beta-gamma bands.
We found that for the set of NMDAR parameters, the
group means, between those with and without the diagno-
sis of NMDAR-antibody encephalitis were signiﬁcantly dif-
ferent (P = 0.047; 2 = 25.17). Importantly, when these
tests were applied to the AMPA receptor parameter sets,
no group differences in our multivariate response variables
were observed (P = 0.29; 2 = 17.4). Similarly, the analysis
reported no group differences in GABAA receptor param-
eter values (P = 0.56; 2 = 13.4). Thus we identiﬁed a group
effect of NMDAR-antibody encephalitis that was selective
to the NMDAR parameter set using DCMs that map from
neuronal synaptic dynamics to empirical EEG recordings.
In Fig. 3A we display the individual parameters from each
set (NMDA, AMPA and GABAA) for each participant—
where the aggregate NMDA parameter effect is shown by
weighting each individual’s estimate set with the canonical
vector for the corresponding channel. The group separation
is predominantly in terms of NMDA parameters (Fig. 3A
and Supplementary Fig. 3). Here we also observe that the
connectivity parameters decrease, commensurate with the
hypothesized pathophysiological receptor hypofunction in
this autoimmune disorder.
To serve as a useful clinical tool, these aberrant synaptic
parameters should be distinguishable on an individual level.
For our individual-level analysis we selected a subset of our
NMDAR-antibody encephalitis patients. Speciﬁcally, we se-
lected only those patients whose EEG was acquired during
the initial acute phase of the illness (53 months since
symptom onset, Supplementary Table 1). This set included
19 of our total 29 patients, with the 10 removed patients
corresponding to chronic or recovering phases of the illness
(Supplementary Table 1). When compared to non-channel
related encephalopathy, 15 of these 19 patients showed a
linear separation based on the DCM parameters (Fig. 3B).
Importantly, we were able to identify, post hoc, the mis-
characterization of those four patients as having prominent
high occipital alpha power (Supplementary Fig. 5). If we
account for alpha power on the scalp, we can successfully
predict the clinical diagnosis of our entire patient cohort in
the acute phase of illness.
Group effects: a parametric empirical
Bayesian approach
To conclude that AMPA and GABAA receptors are not
affected by the presence of NMDAR-antibodies, a
Bayesian analysis is required that allows us to ‘accept the
null’ hypothesis. In other words, a Bayesian analysis allows
us to establish the absence of a group effect. Thus, we
applied to these models an analysis that returns the
probability of an effect at all parameters (rather than
the probability of no-effect as in the classical statistical
CVA-based test above). This Bayesian approach uses
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parametric empirical Bayes (Friston et al., 2016b), which
allows for random effects of model parameters at the group
level. In order to compute these probabilities, the paramet-
ric empirical Bayes scheme performs a search over all pos-
sible group (second-level) effects—postulating that any
combination of parameters might deliver an effect of
NMDAR-antibody encephalitis. This approach effectively
re-estimates model parameters at an individual level for
any combination of group effects and uses Occam’s razor
to reduce the second level effects until only meaningful par-
ameters that contribute to group differences are retained
(Fig. 3C). We tested for the most parsimonious model
that exhibited group effects both in terms of an effect of
NMDAR-antibody encephalitis and in terms of the pres-
ence of encephalopathy. Remarkably, for the beta-gamma
models the signiﬁcant group effects of NMDAR-antibody
encephalitis were observed solely in NMDA parameters.
While in contrast, the group effect of encephalopathy was
expressed across our range of receptors–as would be ex-
pected from our heterogeneous encephalopathy aetiologies
(Fig. 3C and Supplementary Table 2). In particular ﬁve
NMDA parameters showed signiﬁcantly decreased function
in the anti-NMDAR encephalitis group. These parameters
were the rate of channel opening and closing at the right
parietal, right prefrontal and left prefrontal sources as well
as the intrinsic connection to NMDARs at excitatory neu-
rons in the right parietal and left prefrontal source. For the
delta-theta models no signiﬁcant group effects were
observed (Supplementary Fig. 6), indicating a lack of dis-
criminability across NMDA condition for this data feature.
Figure 3 Receptor fingerprints from DCM parameters. (A) Our DCMs contained parameters relating to three major receptor types,
namely NMDA, AMPA and GABAA. Here we show the linear combination of each parameter set that best described the partition amongst the
groups. Our plots show each parameter scaled by the canonical vector (Supplementary Fig. 1). Each of our patients are represented by either a
red sphere (NMDAR-antibody encephalitis diagnosis) or a grey sphere (for both other encephalopathy and neurological patient controls).
Statistically, only the NMDA parameter sets showed any significant multivariate difference between groups. (B) Using parametric empirical Bayes,
we tested for a group difference of NMDAR-antibody encephalitis while accounting for the presence or absence of encephalopathy in general
using all patient records. We used a model search across group-effects to determine which parameters in our DCM showed significant group
differences both in terms of NMDAR-antibody encephalitis status (present in 29 records) and encephalopathy status (present in 47 records). The
top bar charts show the Bayesian covariate, which are reduced via model comparison to leave only those significant effects for each group class.
The lower bar charts indicate group effect probabilities for each parameter with a significance limit set to 40.95 probability. The insets highlight
the set of receptors that exhibit significant group effects. We show that only the NMDA parameters show significant effects for the NMDAR-
antibody encephalitis while all three ion channels are significant predictors of encephalopathy. (B) To investigate individual patient classification, we
tested NMDAR-antibody encephalitis patients using only those EEG records obtained within the ‘acute phase’ (53 months since symptom onset,
n = 19, see Supplementary Table 1). Fifteen of these 19 patients (red spheres) could be distinguished from the encephalopathic controls (grey
spheres). We determined that the misclassifications (striped symbols) could be attributed to a high amplitude occipital alpha rhythm in occipital
regions (Supplementary Fig. 5). By accounting for this confound, an accurate class label could be applied to all of our acute patients.
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Effects on inhibitory interneurons
One prominent hypothesis is that direct NMDAR hypo-
function in inhibitory interneurons leads to disinhibition
in corticolimbic regions, underpinning symptoms in schizo-
phrenia (Olney et al., 1999; Benes and Berretta, 2001;
Lewis et al., 2004; Woo and Crowell, 2005; Coyle, 2006;
Homayoun and Moghaddam, 2007; Nakazawa et al.,
2012). However, ﬁndings remain mixed in schizophrenia
(Schwarcz et al., 2001; Volk et al., 2002), and
in vitro studies of the effect of patient-derived NMDAR
antibodies (Hughes et al., 2010; Moscato et al., 2014)
have shown broad effects on both excitatory and inhibitory
neurons, with no cell type selectivity. The alternative
hypothesis is that NMDAR hypofunction on pyramidal
cells consequently leads to disrupted efferent drive to
interneurons and causes abnormal synchronization of
feedback inhibition and ﬁring in the inhibitory inter-
neuron population (Gonzalez-Burgos and Lewis, 2012), in
turn leading to pyramidal cell hyperexcitability. This
accords with the relatively weak NMDA contribution
to fast synaptic activation of inhibitory interneurons
(Nyiri et al., 2003; Rotaru et al., 2012), and animal
models of cell-speciﬁc NMDAR effects (Billingslea et al.,
2014).
To investigate this mechanism further in our model, we
examined the predicted ﬁring pattern of the inhibitory cell
populations by simulating their population activity and the
spectral output (Supplementary Fig. 9). It is important to
note that the spectral output of the inhibitory interneurons
does not directly contribute to scalp-measured EEG because
of their dendritic arborization topology. However, we can
readily simulate their contributing dynamic at the level of
the neural mass directly. Interestingly, this shows that in our
patients with NMDAR-antibody encephalitis, there is a sup-
pression of inhibitory cell ﬁring across the beta band
compared to normal controls. These cell-speciﬁc spectral
changes provide support for the hypothesis that there is
decreased inhibitory cell synchronization as a knock-on
effect of pyramidal cell NMDAR hypofunction. Unlike the
consistent effect seen on the pyramidal cell NMDA conduct-
ance, there is no consistent parameterization of this spectral
effect in the inhibitory cells (i.e. it arises from a mixture of
non-linear parameter effects). Nonetheless we can recover
this effect through simulating the dynamics of this cell
population.
Effects on system stability
We also considered whether the present pathological com-
bination of parameters leads to a more unstable system in
the NMDAR antibody encephalitis patients. The eigenspec-
trum from the Jacobian shows, as anticipated, that the
NMDAR parameterizations result in closer to unstable
dynamics compared to the other groups (Supplementary
Fig. 8).
Discussion
Our results suggest that standard clinical EEG can serve to
accurately reveal unobservable synaptic pathology, utilizing
a biophysical model of connected cortical ensembles and
Bayesian inversion techniques. We ﬁrst identiﬁed a speciﬁc
change in the spectral characteristics of resting-state EEG
signals in patients with NMDAR-antibody encephalitis. We
then used these spectral signatures to constrain individual
models of ionotropic receptor function (Friston et al.,
2012). The parameter estimates, recovered from DCMs of
the cross-spectral densities, were used to identify the func-
tional status of NMDA, AMPA and GABAA receptors. This
revealed, using a Bayesian approach, a speciﬁc effect in
NMDAR conductance in a patient group in which
NMDA antibodies had been detected and in which
NMDAR-antibody encephalitis had been the ﬁnal diagno-
sis. Crucially, we were able to identify, based on individual
parameter estimates, patients in the acute phase of the ill-
ness with high sensitivity when accounting for effects in the
alpha band. We could discriminate the NMDAR-antibody
encephalitis patients from patients with a diverse range of
encephalopathic illnesses. These ﬁndings provide novel evi-
dence for the diagnostic and prognostic capabilities of clin-
ical EEG using a model-based approach, and extend our
previous ﬁndings on magnetoencephalographic-based chan-
nelopathy detection in genetic channelopathy case studies
(Gilbert et al., 2016).
Our analysis is motivated by previous neuroimaging stu-
dies of patients with NMDAR-antibody encephalitis that
have revealed deﬁcits in resting state functional MRI con-
nectivity in the default mode network (Finke et al., 2013)
and by studies in the electrophysiological domain that have
revealed distinct patterns in spectro-temporal EEG charac-
teristics. Speciﬁcally, a feature reminiscent of the neonatal
‘delta-brush’ of prematurity has been identiﬁed that is asso-
ciated with prolonged hospitalization (Schmitt et al., 2012)
and potential for status epilepticus (Herlopian et al., 2016).
This feature comprises enhanced 20–30Hz (beta band) sig-
nals superimposed upon a delta rhythm (Van Noord et al.,
2016). Here we analysed both of these high and low fre-
quency bands within nodes of the default mode network
(Brookes et al., 2011) and characterized the neurophysio-
logical processes that could generate the observed response
in these bands (Moran et al., 2008). Interestingly, our
model-based estimates of NMDAR function in patients
with NMDAR-antibody encephalitis produce less stable dy-
namics, which may reﬂect the increased propensity to seiz-
ures in these individuals. This alteration in low and high
frequency bands and their coupling may contribute directly
to the early cognitive and perceptual changes observed in
NMDAR-antibody encephalitis. In particular, psychosis is a
common symptom that occurs early in the disease (Kayser
and Dalmau, 2016). We have previously used DCM in a
rodent ketamine model of psychosis (Moran et al., 2015) to
show that enhanced high-frequency oscillations are
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associated with NMDAR-based reduction in brain connect-
ivity. This loss of NMDAR function may thus, overall,
contribute to a loss in signal integration among brain re-
gions, which our results suggest may be mediated by a
combination of effects on pyramidal cells and a consequent
suppression of inhibitory interneuron activity. Moreover,
this observation of enhanced high-frequency neuronal ac-
tivity may relate to the hypermetabolic processes observed
in PET studies of these patients (Leypoldt et al., 2012;
Heine et al., 2015). In our statistical analyses (Fig. 3), we
characterized the overall network response of these
receptors. We discriminate effects of NMDAR dynamics
(parameters specifying NMDAR time constants and non-
linear voltage gating) from effects on NMDAR conduct-
ance (modelled by cell- and region-speciﬁc parameters).
However, the dynamic causal model is agnostic as to the
exact mechanism of NMDAR hypofunction. We localize
effects to a decreased NMDAR conductance, but cannot
discriminate between functional antagonism of receptors
versus receptor internalization, although the latter mechan-
ism has signiﬁcant experimental support (Moscato et al.,
2014). Future work will expand on the anatomical foci
revealed by DCM parameters, which may map to the het-
erogeneities in clinical presentation of these patients.
Currently there is no available technology to assess the
synaptic components of cortical neuronal networks in
humans non-invasively. Whilst limited assessments of
neurotransmitter and receptor levels can be made using
magnetic resonance spectroscopy and PET, respectively,
these techniques do not directly measure synaptic activity
and can be applied only to a limited set of neurotransmit-
ters and receptors. NMDARs, which are crucial for plasti-
city and memory (Paoletti et al., 2013), are among those
ionotropic receptors for which quantitative investigation
in vivo remain absent. Several types of ion channels deli-
cately balance the excitation and inhibition of neurons to
promote a global dynamic state at the edge of criticality
(Deco et al., 2013) and changes in excitatory/inhibitory
ratios have been linked to neuropsychiatric diseases as di-
verse as autism (Yizhar et al., 2011) and schizophrenia
(Lisman, 2012). Aberrant function of a single ion channel
can lead to various pathophysiological processes, where
in the case of NMDARs, hyperactivity increases intracellu-
lar calcium, which can lead to excitotoxic cascades in
ischaemic stroke (Shi et al., 2013) and Alzheimer’s
disease (Talantova et al., 2013), while hypoactive signalling
at inhibitory interneurons in the prefrontal cortex may con-
tribute to abnormal circuit function in schizophrenia
(Friston et al., 2016a). Here we used one class of
disease from a recently discovered family of autoim-
mune neurological disorders to provide a rare but
remarkably speciﬁc ‘template disorder’ and lesion model,
against which our non-invasive ion channel assay could
be tested.
Autoimmune encephalopathies result from the endogen-
ous production of antibodies against speciﬁc ion channel
components, with a diverse range of antibodies against
components of the NMDAR (Titulaer et al., 2013),
AMPA receptor (Graus et al., 2010), LGI1 or CASPR2
(Tan et al., 2008; Irani et al., 2010a), glycine (Carvajal-
Gonza´lez et al., 2014) and GABAA/B receptor (Pettingill
et al., 2015) all recently identiﬁed in patients with neuro-
logical and psychiatric symptoms. Current diagnostic
assays for autoimmune encephalopathies involve serum
and/or CSF analysis for antibody detection. In future ex-
tensions we aim to show that our model-based assay can
distinguish receptor abnormalities between these autoim-
mune subtypes. Future developments of our modelling ap-
proach could also include structural connectivity (Heine
et al., 2015) measures from patients where we embed
neural masses in anatomically-derived connected networks
(Jirsa et al., 2010).
These large-scale network models of brain activity con-
trast with our four-source DCM, where we trade-off net-
work complexity for parameter identiﬁability of speciﬁc
receptor types. The key value of the DCM method outlined
here is related to the inversion of these models. We make
use of these models in the forward direction—to generate
data—but crucially, we also solve the inverse problem and
identify parameter values on a patient-speciﬁc basis (Gilbert
et al., 2016). Our inversion routine reveals parameter co-
variances by stipulating a large multivariate Gaussian par-
ameter space. We have previously shown that DCMs’
parameters co-vary within ranges that render them identi-
ﬁable (Moran et al., 2011a). This is reiterated here—since
we demonstrate selective identiﬁcation of an abnormal ion
channel (at NMDARs), without signiﬁcant effects present
in AMPA or GABAA receptor parameter values. In
NMDAR-antibody encephalitis, cell cultures treated with
patient CSF reveal a reduction in surface NMDAR density
through receptor internalization (Hughes et al., 2010), lead-
ing to a selective decrease in NMDAR-mediated currents
without impairment of other synaptic processes (Irani and
Vincent, 2011). It is these molecular mechanisms that
are the most likely putative explanation for our model
parameter changes. Although NMDAR activity can be
modulated in a range of encephalopathic illnesses, clearly
the deﬁcits in NMDAR conductance in NMDAR-antibody
encephalitis are severe and signiﬁcant enough to yield an
accurate biomarker allowing segregation of these patients
from other matched encephalopathic control patients in our
cohort.
Our current results from routinely acquired EEG data
already demonstrate that our approach provides a feasible
assay for individual clinical assessment. Given that EEG is
ubiquitously available and cost-efﬁcient, our results
imply that neuro-modelling of EEG data could provide
clinically useful tests for a wide range of brain disorders.
Looking forward, our development of computational
EEG ﬁngerprints of individual NMDAR status may
also yield new mechanistic insights into the aetiology
and progression of other neurological and psychiatric
diseases.
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